Mianyang Central Hospital

Running trials

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

  NCT07876557· Phase 2· Shanghai Junshi Bioscience Co., Ltd.· Source

• Not yet recruiting

  A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

  NCT07760155· Phase 2· Shanghai Escugen Biotechnology Co., Ltd· Source

• Recruiting

  A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

  NCT07564596· Phase 1/2· Climb Bio, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

  NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source

• Recruiting

  Phase II Trial of RC1416 Injection in Asthma

  NCT07403487· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source

• Recruiting

  Phase II Study of RC1416 Injection in COPD

  NCT07402551· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source

• Not yet recruiting

  Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT07381582· Early phase 1· Peking Union Medical College Hospital· Source

• Recruiting

  A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

  NCT07323173· Phase 1· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Not yet recruiting

  Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

  NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

  NCT07327034· Phase 2· Abbisko Therapeutics Co, Ltd· Source

• Recruiting

  A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT07010263· Phase 3· Akeso· Source

• Recruiting

  A Study of SCTB35 in Patients with Systemic Lupus Erythematosus

  NCT06841042· Phase 1/2· Sinocelltech Ltd.· Source

• Recruiting

  A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

  NCT06532006· Phase 3· Shanghai Henlius Biotech· Source

• Active, not recruiting

  PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

  NCT06616532· Phase 3· Biotheus Inc.· Source

• Active, not recruiting

  A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Active, not recruiting

  Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

  NCT06360458· Phase 3· Wan-Jin Chen· Source

• Active, not recruiting

  PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

  NCT06419621· Phase 3· Biotheus Inc.· Source

• Active, not recruiting

  A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source

• Recruiting

  D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

  NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

  NCT06155084· Phase 1/2· Hinova Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

  NCT05990127· Phase 3· Akeso· Source

• Recruiting

  Clinical Study of Oncolytic Virus in Glioblastoma

  NCT07145047· Phase 1/2· Mianyang Central Hospital· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

• Recruiting

  Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

  NCT06569524· Phase 2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Recruiting

  FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension

  NCT05590871· Shanghai Hongdian Medical CO., LTD· Source

• Active, not recruiting

  A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

  NCT05652894· Phase 3· Taizhou Hanzhong biomedical co. LTD· Source

• Recruiting

  Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

  NCT05334277· Phase 2· Sun Yat-sen University· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

  NCT05346224· Phase 3· Shanghai Henlius Biotech· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

  NCT04906434· Phase 1· Abbisko Therapeutics Co, Ltd· Source

• Active, not recruiting

  KN035 for dMMR/MSI-H Advanced Solid Tumors

  NCT03667170· Phase 2· 3D Medicines (Sichuan) Co., Ltd.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Lupus (SLE)3 recruiting
• COPD2 recruiting
• Liver and biliary tract cancer2 recruiting
• Prostate cancer2 recruiting
• Asthma1 recruiting
• Colorectal cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Gout1 recruiting
• High blood pressure1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Efficacy and Safety of CP006 Inhalation Powder in Participants With Asthma

  NCT07807007· Phase 2· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

  NCT06848400· Nanfang Hospital, Southern Medical University· Source

• Completed

  Budesonide/Formoterol Inhalation Powder in Adults With Asthma

  NCT07790159· Phase 3· Shanghai Xin Huanghe Pharmaceutical Co., Ltd.· Source

• Completed

  Head Position After Endovascular Therapy

  NCT06115707· Zhengzhou Yuan· Source

• Completed

  Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)

  NCT06037889· Phase 3· Peking Union Medical College Hospital· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis

  NCT06068478· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.

  NCT05987371· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke

  NCT05631847· Sichuan Academy of Medical Sciences· Source

• Completed

  Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

  NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· RemeGen Co., Ltd.· Source

• Completed

  rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

  NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source

• Completed

  A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

  NCT05459844· Phase 3· Sinotau Pharmaceutical Group· Source

• Terminated

  A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

  NCT05292196· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

  NCT04908787· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Hydrocephalus7 works · 0 trials